Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Supernus Pharmaceuticals stock | 22.36

Own Supernus Pharmaceuticals stock in just a few minutes.

Posted

Fact checked

Supernus Pharmaceuticals, Inc is a drug manufacturers—specialty & generic business based in the US. Supernus Pharmaceuticals shares (SUPN) are listed on the NASDAQ and all prices are listed in US Dollars. Supernus Pharmaceuticals employs 464 staff and has a trailing 12-month revenue of around USD$477.3 million.

How to buy shares in Supernus Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Supernus Pharmaceuticals. Find the stock by name or ticker symbol: SUPN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Supernus Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$22.36, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Supernus Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Supernus Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Supernus Pharmaceuticals share price

Use our graph to track the performance of SUPN stocks over time.

Supernus Pharmaceuticals shares at a glance

Information last updated 2020-11-23.
Latest market close USD$22.36
52-week range USD$13.12 - USD$25.82
50-day moving average USD$20.7809
200-day moving average USD$22.4793
Wall St. target price USD$27.75
PE ratio 8.6224
Dividend yield N/A (0%)
Earnings per share (TTM) USD$2.411

Buy Supernus Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Supernus Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Supernus Pharmaceuticals price performance over time

Historical closes compared with the close of $22.36 from 2020-11-16

1 week (2020-11-16) N/A
1 month (2020-10-23) N/A
3 months (2020-08-23) N/A
6 months (2020-05-23) N/A
1 year (2019-11-23) N/A
2 years (2018-11-23) N/A
3 years (2017-11-23) N/A
5 years (2015-11-23) N/A

Is Supernus Pharmaceuticals under- or over-valued?

Valuing Supernus Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Supernus Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Supernus Pharmaceuticals's P/E ratio

Supernus Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 9x. In other words, Supernus Pharmaceuticals shares trade at around 9x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Supernus Pharmaceuticals's PEG ratio

Supernus Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.47. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Supernus Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Supernus Pharmaceuticals's EBITDA

Supernus Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$197.4 million.

The EBITDA is a measure of a Supernus Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Supernus Pharmaceuticals financials

Revenue TTM USD$477.3 million
Operating margin TTM 38.37%
Gross profit TTM USD$376.1 million
Return on assets TTM 8.75%
Return on equity TTM 20.43%
Profit margin 27.09%
Book value $13.459
Market capitalisation USD$1.1 billion

TTM: trailing 12 months

Shorting Supernus Pharmaceuticals shares

There are currently 5.2 million Supernus Pharmaceuticals shares held short by investors – that's known as Supernus Pharmaceuticals's "short interest". This figure is 1.5% up from 5.1 million last month.

There are a few different ways that this level of interest in shorting Supernus Pharmaceuticals shares can be evaluated.

Supernus Pharmaceuticals's "short interest ratio" (SIR)

Supernus Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Supernus Pharmaceuticals shares currently shorted divided by the average quantity of Supernus Pharmaceuticals shares traded daily (recently around 356695.53571429). Supernus Pharmaceuticals's SIR currently stands at 14.56. In other words for every 100,000 Supernus Pharmaceuticals shares traded daily on the market, roughly 14560 shares are currently held short.

However Supernus Pharmaceuticals's short interest can also be evaluated against the total number of Supernus Pharmaceuticals shares, or, against the total number of tradable Supernus Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Supernus Pharmaceuticals's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Supernus Pharmaceuticals shares in existence, roughly 100 shares are currently held short) or 0.1474% of the tradable shares (for every 100,000 tradable Supernus Pharmaceuticals shares, roughly 147 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Supernus Pharmaceuticals.

Find out more about how you can short Supernus Pharmaceuticals stock.

Supernus Pharmaceuticals share dividends

We're not expecting Supernus Pharmaceuticals to pay a dividend over the next 12 months.

Supernus Pharmaceuticals share price volatility

Over the last 12 months, Supernus Pharmaceuticals's shares have ranged in value from as little as $13.12 up to $25.82. A popular way to gauge a stock's volatility is its "beta".

SUPN.US volatility(beta: 1.37)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Supernus Pharmaceuticals's is 1.3732. This would suggest that Supernus Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Supernus Pharmaceuticals overview

Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in neurology and psychiatry in the United States. The company offers Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and in children 6 to 17 years of age; and Trokendi XR, an extended release topiramate, which is used for the prophylaxis of migraine headache, as well as for the treatment of epilepsy. Its product candidates comprise SPN-812, a viloxazine hydrochloride, which has completed phase III clinical trial that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-809, a viloxazine hydrochloride, which is in phase II ready clinical trial for the treatment of depression; SPN-604 extended release oxcarbazepine, which is in phase III clinical trial for the treatment of bipolar disorder; and SPN-817 that is in phase I clinical trial to treat severe pediatric epilepsy disorders. The company markets its products through pharmaceutical wholesalers and distributors. It has a development and option agreement with Navitor Pharmaceuticals, Inc. to conduct a phase II clinical program for NV-5138 in treatment-resistant depression. Supernus Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Rockville, Maryland.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site